ZURA BIO LIMITED Other Nonoperating Income (Expense)
ZURA BIO LIMITED (ZURA) reported Other Nonoperating Income (Expense) of $1.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-11
- ZURA BIO LIMITED other nonoperating income (expense) for the quarter ending 2026-06-30 was $1.02M, a 188.64% increase year-over-year.
- ZURA BIO LIMITED other nonoperating income (expense) for the quarter ending 2026-03-31 was -$43.00K.
- ZURA BIO LIMITED other nonoperating income (expense) for the quarter ending 2025-09-30 was -$47.00K, a 313.64% decline year-over-year.
- ZURA BIO LIMITED other nonoperating income (expense) for the quarter ending 2025-06-30 was $352.00K, a 17500.00% increase year-over-year.
- ZURA BIO LIMITED other nonoperating income (expense) for fiscal 2023 was $2.08M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 5 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 6 month as first filed | Other Nonoperating Income (Expense) 8 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 9 month as first filed | Other Nonoperating Income (Expense) 11 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.02M 10-Q · filed 2026-08-11 | $973.00K 10-Q · filed 2026-08-11 | ||||||||
| 2026-03-31 | -$43.00K 10-Q · filed 2026-05-07 | |||||||||
| 2025-09-30 | -$47.00K 10-Q · filed 2025-11-13 | $305.00K derived: sum of 2 quarters · filed 2026-08-11 | $300.00K 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | $352.00K 10-Q · filed 2026-08-11 | $347.00K 10-Q · filed 2026-08-11 | ||||||||
| 2025-03-31 | -$5.00K 10-Q · filed 2026-05-07 | |||||||||
| 2024-09-30 | $22.00K 10-Q · filed 2025-11-13 | $24.00K derived: sum of 2 quarters · filed 2025-11-13 | $47.00K 10-Q · filed 2025-11-13 | $2.13M derived: sum of 4 quarters · filed 2025-11-13 | ||||||
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-14 | $25.00K 10-Q · filed 2025-08-14 | $2.11M derived: sum of 3 quarters · filed 2025-08-14 | $2.10M derived: sum of 4 quarters · filed 2025-08-14 | ||||||
| 2024-03-31 | $23.00K 10-Q · filed 2025-05-08 | $2.10M derived: sum of 2 quarters · filed 2025-05-08 | $2.10M derived: sum of 3 quarters · filed 2025-05-08 | $2.11M derived: sum of 4 quarters · filed 2025-05-08 | ||||||
| 2023-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.08M derived: sum of 2 quarters · filed 2024-11-07 | $2.08M derived: sum of 3 quarters · filed 2024-11-07 | $2.08M 10-K · filed 2024-03-28 | ||||||
| 2023-09-30 | -$4.00K 10-Q · filed 2024-11-07 | $1.92M 10-Q · filed 2023-11-13 | $3.00K derived: sum of 2 quarters · filed 2024-11-07 | -$7.00K 10-Q · filed 2024-11-07 | -$279.00K 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | $7.00K 10-Q · filed 2024-08-13 | -$120.00K 10-Q · filed 2023-08-14 | -$3.00K 10-Q · filed 2024-08-13 | -$2.20M 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | -$10.00K 10-Q · filed 2024-05-09 | -$2.08M 10-Q · filed 2023-05-12 | ||||||||
| 2022-12-31 | -$171.00K 10-K · filed 2024-03-28 | |||||||||
| 2022-09-30 | -$34.00K 10-Q · filed 2023-11-13 | -$32.00K derived: sum of 2 quarters · filed 2023-11-13 | -$32.00K 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | $2.00K 10-Q · filed 2023-08-14 | $2.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |